Skip to main content
. 2021 Feb 2;22(3):1472. doi: 10.3390/ijms22031472
A2AP alpha 2-antiplasmin
ACS acute coronary syndrome
CAD coronary artery disease
FXIII/FXIIIa coagulation factor XIII/activated coagulation factor XIII
GTT Global Thrombosis Test
MACE major cardiovascular adverse events
MI myocardial infarction
PAI-1/-2 Plasminogen activator inhibitor-1/-2
ROTEM Thromboelastometry
TAFI Thrombin activatable fibrinolysis inhibitor
TEG Thromboelastography
VTE venous thromboembolism